News
4d
GlobalData on MSNGSK’s Blenrep combos approved for multiple myeloma in EUThe combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...
Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...
On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...
GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...
11d
Stocktwits on MSNGSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay OptimisticRetail chatter around GSK picked up on Thursday after Blenrep, one of its cancer drugs, hit a roadblock with U.S. regulators.
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.
SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...
11d
GlobalData on MSNGSK’s Blenrep faces setback as FDA cancer committee votes against approvalOncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) ...
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results